Thymoma type B3
MONDO:0006458Also known as well-differentiated thymic carcinoma, atypical thymoma, or epithelial thymoma, this type of thymoma displays morphologic characteristics of a well-differentiated carcinoma. The majority of cases occur in the anterior mediastinum as Masaoka stage II or stage III tumors. It is almost always invasive, it recurs frequently, and metastasizes in approximately 20% of the cases.
Also known as: atypical thymoma, epithelial malignant thymoma, epithelial thymoma, malignant thymoma type B3, squamoid thymoma, thymoma type B3, well differentiated thymic carcinoma, well-differentiated thymic carcinoma
1575 clinical trials for this condition and its sub-types, 3 tagged with Thymoma type B3 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New immunotherapy combo targets rare cancers left behind by progress
Disease control OngoingThis phase 2 trial tests a combination of two immunotherapy drugs, domvanalimab and zimberelimab, in people with five types of advanced rare cancers (peritoneal mesothelioma, gestational trophoblastic tumor, anaplastic thyroid carcinoma, neuroendocrine tumors, and thymic carcinom…
Phase 2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Immunotherapy drug nivolumab tested for rare thymus cancers
Disease control OngoingThis phase 2 trial is testing the immunotherapy drug nivolumab in 55 patients with type B3 thymoma or thymic carcinoma that has worsened after platinum-based chemotherapy. The main goal is to see if nivolumab can stop the cancer from growing for at least 6 months. Researchers wil…
Phase 2 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC